Windgap Medical last week announced a strategic partnership with ALK-Abelló to commercialize its epinephrine auto-injector to treat anaphylactic shock.
ALK will have exclusive, worldwide sales and distribution rights for the Windgap epinephrine auto-injector through the deal in exchange for technical and sales milestone payments and tiered royalties on net sales in the U.S. The companies will also split net profit for products sold outside of the U.S.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!